About the Company

Gruppo Colorobbia, Italy is active in research and development, prototyping and production of nano-based products to be used in the industrial fields of pharmaceuticals, nano-medicine, coatings and environmental protection, as well as to provide services in term of research, chemical and chemical-physical analysis, compliance with environmental and safety regulations in force, IT and process plant engineering.

One of its main projects – and the focus of the pilot – is NANOMED. This ia large research project based on in-house resources from the company and funding by different cooperative projects, aims to create a technology platform providing an integrated and modular system, for the diagnosis and treatment (theranostic) of cancer and nervous system diseases. It is a nanotechnology based system using a combination of targeted and controlled drug delivery, hyperthermia and radiofrequency and laser imaging methods. The technology platform will lead to different products, including a contrast agent, a formulation (drug), a cell therapy system and a portable and integrated medical device to produce the cell therapy system.

The following interviews with Giovanni Baldi, Director – Ce.Ri.Col – Colorobbia Consulting Research Centre – focus on different RRI aspects but on safety and stakeholder engagement n particular.

“We consider pivotal to our R&D efforts an open and continuous dialogue with stakeholders, patients, in the first place, and regulators, health-care professionals, policy makers, media, the society at large. It is vital to improve functionalities, quality and reliability, acceptability, of the NanoMed technologies and products.
With PRISMA we learned the importance of focusing on the ethical and social impacts of NanoMed since the early phases of the development, to become responsive and trustworthy toward needs and requests from users and society. This experience has convinced us of the strategic value of RRI for NanoMed and our organization.”